Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26180100 | 0.89 | PIK3CD (0.48) | PIK3CDPDE4BPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29005485 | 0.88 | PIK3CD (0.49) | PIK3CDPDE4BPIK3CAPIK3CBPIK3CG | |
| SCHEMBL25028574 | 0.86 | PDE4B (0.46) | PIK3CDPDE4BPIK3CAPIK3CBPIK3CG | |
| SCHEMBL25029079 | 0.82 | PDE4B (0.48) | PIK3CDPDE4BPIK3CAPIK3CBPIK3CG | |
| SCHEMBL25322052 | 0.81 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30508814 | 0.81 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL25318945 | 0.81 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29005447 | 0.80 | PDE4D (0.49) | PIK3CDPDE4BPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1821707 | 0.79 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1821709 | 0.79 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667624-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | PIK3CD 4102/4885PDE4B 1005/4885PIK3CA 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.